CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Efalizumab

Efalizumab

Last Updated: June 19, 2007

Result type: Reports

Project Number: SF0102-000

Product Line: Reimbursement Review

Generic Name: Efalizumab

Brand Name: Raptiva

Manufacturer: Serono Canada Inc.

Therapeutic Area: Psoriasis, moderate to severe chronic plaque

Indications: Psoriasis, moderate to severe chronic plaque

Submission Type: Request For Advice

Project Status: Complete

Efalizumab

Files